Detalhe da pesquisa
1.
The pathogenesis of rheumatoid arthritis.
Immunity
; 55(12): 2255-2270, 2022 12 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36516818
2.
Immunopathogenesis of Rheumatoid Arthritis.
Immunity
; 46(2): 183-196, 2017 02 21.
Artigo
Inglês
| MEDLINE | ID: mdl-28228278
3.
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
Lancet
; 403(10429): 838-849, 2024 Mar 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38364839
4.
Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.
Lancet
; 401(10391): 1878-1890, 2023 06 03.
Artigo
Inglês
| MEDLINE | ID: mdl-37156255
5.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet
; 401(10370): 25-37, 2023 01 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36493791
6.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artigo
Inglês
| MEDLINE | ID: mdl-36495881
7.
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
N Engl J Med
; 384(13): 1227-1239, 2021 04 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33789011
8.
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Ann Rheum Dis
; 83(6): 760-774, 2024 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38503473
9.
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.
Ann Rheum Dis
; 83(4): 409-416, 2024 Mar 12.
Artigo
Inglês
| MEDLINE | ID: mdl-38123338
10.
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Ann Rheum Dis
; 83(6): 706-719, 2024 May 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38499325
11.
Differences in transcriptional changes in psoriasis and psoriatic arthritis skin with immunoglobulin gene enrichment in psoriatic arthritis.
Rheumatology (Oxford)
; 63(1): 218-225, 2024 Jan 04.
Artigo
Inglês
| MEDLINE | ID: mdl-37137278
12.
Association of the clinical components in the distal interphalangeal joint synovio-entheseal complex and subsequent response to ixekizumab or adalimumab in psoriatic arthritis.
Rheumatology (Oxford)
; 2024 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38341669
13.
Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin ß Receptors.
Immunity
; 42(6): 1100-15, 2015 Jun 16.
Artigo
Inglês
| MEDLINE | ID: mdl-26084025
14.
Translational targeting of inflammation and fibrosis in frozen shoulder: Molecular dissection of the T cell/IL-17A axis.
Proc Natl Acad Sci U S A
; 118(39)2021 09 28.
Artigo
Inglês
| MEDLINE | ID: mdl-34544860
15.
Distinct innate and adaptive immunity phenotypic profile at the circulating single-cell level in Psoriatic Arthritis.
Clin Immunol
; 253: 109679, 2023 08.
Artigo
Inglês
| MEDLINE | ID: mdl-37336253
16.
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Ann Rheum Dis
; 82(12): 1516-1526, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37699654
17.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ann Rheum Dis
; 82(11): 1404-1414, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37696588
18.
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Ann Rheum Dis
; 82(12): 1527-1537, 2023 12.
Artigo
Inglês
| MEDLINE | ID: mdl-37696589
19.
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2022.
Ann Rheum Dis
; 82(5): 594-598, 2023 05.
Artigo
Inglês
| MEDLINE | ID: mdl-36702529
20.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
Ann Rheum Dis
; 82(1): 3-18, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36357155